SCHEMBL15027779

SCHEMBL15027779

CC(C)CCC(CCOC(=O)CCCCCCCCCC(CCCCCCCCCC(=O)OCCC(CCC(C)C)C(C)C)OC(=O)CCCN1CCCCC1)C(C)C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ GAA P10253 1/20 0.37
▸ KMT2A Q03164 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ CYP1A2 P05177 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HRH3 Q9Y5N1 4/20 0.34
▸ LMNA P02545 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ THRA P10827 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ HRH1 P35367 1/20 0.33
▸ TLR2 O60603 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15148303 0.99 ALDH1A1 (0.43) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL15027784 0.95 ALDH1A1 (0.44) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL25989853 0.94 ALDH1A1 (0.43) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL15027761 0.94 ALDH1A1 (0.43) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL15148617 0.93 ALDH1A1 (0.41) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL17123876 0.91 ALDH1A1 (0.41) ALDH1A1L3MBTL1GAAKMT2AMEN1
SCHEMBL15148304 0.91 ALDH1A1 (0.41) ALDH1A1L3MBTL1GAACYP1A2MAPK1
SCHEMBL15148273 0.89 PRKCA (0.41) ALDH1A1L3MBTL1GAASMN1; SMN2LMNA
SCHEMBL15148349 0.89 ALDH1A1 (0.44) ALDH1A1L3MBTL1KMT2AMEN1HRH3
SCHEMBL25989805 0.89 ALDH1A1 (0.44) ALDH1A1L3MBTL1KMT2AMEN1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230256098-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2023-08-17 — — US disclosed
US-20230256098-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2023-08-17 — — US disclosed
US-11679158-B2 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2023-06-20 — — US disclosed
US-11679158-B2 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2023-06-20 — — US disclosed
US-11633479-B2 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2023-04-25 — — US disclosed
US-20220347302-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. 2022-11-03 — — US disclosed
US-11382979-B2 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2022-07-12 — — US disclosed
US-20220175929-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2022-06-09 — — US disclosed
US-20220175930-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2022-06-09 — — US disclosed
US-20220175928-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2022-06-09 — — US disclosed
US-20170233734-A1 NUCLEIC ACID LIPID PARTICLE FORMULATIONS ALNYLAM PHARMACEUTICALS INC (US) 2017-08-17 — — US disclosed
US-20170233734-A1 NUCLEIC ACID LIPID PARTICLE FORMULATIONS ALNYLAM PHARMACEUTICALS INC (US) 2017-08-17 — — US disclosed
US-9687448-B2 Nucleic acid lipid particle formulations ALNYLAM PHARMACEUTICALS, INC. (US) 2017-06-27 — — US disclosed
US-9687448-B2 Nucleic acid lipid particle formulations ALNYLAM PHARMACEUTICALS, INC. (US) 2017-06-27 — — US disclosed
US-20150306039-A1 IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS BANK OF AMERICA, N.A. 2015-10-29 — — US disclosed
US-20150306039-A1 IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS BANK OF AMERICA, N.A. 2015-10-29 — — US disclosed
US-20150273068-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2015-10-01 — — US disclosed
US-20150273068-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2015-10-01 — — US disclosed
WO-2014089239-A1 IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS ALNYLAM PHARMACEUTICALS, INC. (US) 2014-06-12 — — WO disclosed
WO-2013086354-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175929-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885GAA 253/4885
US-11633479-B2 Biodegradable lipids for the delivery of active agents LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885GAA 253/4885
US-11382979-B2 Biodegradable lipids for the delivery of active agents LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885GAA 253/4885
US-20150273068-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885GAA 253/4885
US-20220347302-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885GAA 253/4885
US-20220175930-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885GAA 253/4885
US-20220175928-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885GAA 253/4885
US-11679158-B2 Biodegradable lipids for the delivery of active agents LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885GAA 253/4885
US-20230256098-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885GAA 253/4885
US-20170233734-A1 NUCLEIC ACID LIPID PARTICLE FORMULATIONS LIPA, ABHD16A, CETP ALDH1A1 1813/4885L3MBTL1 1098/4885GAA 617/4885
US-20150306039-A1 IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS LIPA, NPC1L1, CETP ALDH1A1 2297/4885L3MBTL1 1408/4885GAA 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback